The Medical Advisory Panel (MAP) is comprised of pancreatic cancer specialists from across the country. PCCF regularly consults with the MAP for their opinions on new research projects and findings. The MAP provides the scientific support to ensure PCCF passes along helpful and accurate information.
Malcolm J Moore, MD
Dr. Malcolm Moore is the President of BC Cancer Agency. He oversees a comprehensive Cancer Control Program including prevention, screening, diagnosis, treatment and supportive care for the five million citizens of British Columbia.
Dr. Moore is also a practicing medical oncologist, a researcher and clinical pharmacologist involved in drug development work for cancer therapy. He continues to have a clinical practice in gastrointestinal (GI) oncology in addition to his administrative duties. Prior to his appointment as President of BC Cancer Agency, Dr. Moore was Director of the Drug Development Program and Co-Director of the McCain Centre for Pancreatic Cancer at Princess Margaret Hospital in Toronto.
He is also the past President of the International Society of Gastrointestinal Oncology. Over the past two decades, Dr. Moore has been involved in the development of new cancer therapies, has been a principal investigator in a number of practice changing clinical studies, has authored over 250 peer-reviewed publications and has given more than 200 invited lectures worldwide.
Steven Gallinger, M.Sc., MD
Dr. Gallinger is a Hepatobiliary/pancreatic (HPB) surgical oncologist at Princess Margaret Cancer Centre at University Health Network. He is also the Co Chair of PCCF’s PancOne™ research project. He was recently appointed the inaugural Joseph and Wolf Lebovic Chair in Hepato-Pancreatico-Biliary Surgery at University Health Network. He is a Professor of Surgery at the University of Toronto, Head of the HPB Surgical Oncology Program at UHN and Mount Sinai Hospital (MSH) and Chair of the Cancer Care Ontario HPB Community of Practice.
His research interests are primarily in the area of GI cancer genetics and he is co-Director of the Centre for Cancer Genetics at the Samuel Lunenfeld Research Institute, co-PI of the Zane Cohen Familial Gastrointestinal Cancer Registry at MSH and also PI of the Ontario Pancreas Cancer Study. He is a member of the NIH funded Pancreas Cancer Genetic Epidemiology consortium and was recently appointed as Lead of the Translational Research Initiative in pancreas cancer, termed PanCuRx.
Dr. Gallinger is also the Co-Director of the McCain Centre for Pancreatic Cancer at the Princess Margaret, a chair of the GI Cancer Program at PMH and was recently appointed Chair of the GI committee for National Cancer Institute of Canada [NCIC].
Dan Renouf, MD, MPH
Dr. Renouf is a medical oncologist at the British Columbia Cancer Agency, Vancouver Centre, Co-Director of Pancreas Cancer BC and an Assistant Professor at the University of British Columbia, Department of Medicine. He is also the Co Chair of PCCF’s PancOne™ research project.
He received his Doctor of Medicine from the University of Alberta and completed his internal medicine and medical oncology training at the University of British Columbia and British Columbia Cancer Agency.
He undertook further training in early drug development and gastrointestinal oncology at Princess Margaret Hospital and the University of Toronto, and obtained a Masters of Public Health from Harvard University. His research interests include developmental therapeutics and molecular epidemiology within gastrointestinal cancers, with a focus on pancreatic cancer. Click here to read his journey.
David Schaeffer, MD
Dr. Schaeffer is an Assistant Professor in the Department of Pathology & Laboratory Medicine at The University of British Columbia and heads the Division of Anatomic Pathology at Vancouver General Hospital. He is also a member of PCCF’s PancOne™ research project.
Dr. Schaeffer obtained his medical degree from the Johanna’s Guenzberg University of Mainz, Germany. After a Residency Program in Anatomical Pathology in Vancouver he completed his Gastrointestinal Pathology Fellowship at Mount Sinai Hospital.
Dr. Schaeffer is a co-Director of the Pancreas Centre BC and also heads the Gastrointestinal Biobank (GIBB) at Vancouver General Hospital. He has an active research program focusing predominantly on translational research in colonic and pancreatic cancer.
Patricia Tang, MD
Dr. Tang is a Medical Oncologist at the Tom Baker Cancer Centre and Clinical Associate Professor in the Departments of Oncology and Medicine at the Cumming School of Medicine, University of Calgary. Dr. Tang is also a member of PCCF’s PancOne™ research project. She graduated with distinction from the University of Alberta’s medical school, and completed a fellowship in gastrointestinal oncology and drug development at the Princess Margaret Hospital and the University of Toronto, Canada.
Dr. Tang was awarded the 2016 Ralph Meyer Phase III Program Young Investigator Award from the Canadian Clinical Trials group. Currently, she is a full member of the Arnie Charbonneau Cancer Institute and has won many teaching awards. Her academic interests include health services research and early phase clinical trials.
Jim Biagi, MD
Dr. Biagi is a medical oncologist and Deputy department head, department of oncology, Queens University and Kingston Regional Cancer Centre Institute, medical oncologist, Cancer Research Institute at Queen’s University and co-chair, Cancer Care Ontario Gastrointestinal Cancer Disease Site Group Cancer Centre of Southeastern Ontario, Kingston General Hospital. Dr. Biagi is also a member of PCCF’s PancOne™ research project.
He has found that a delay between surgery and chemotherapy can lead to a decrease in overall survival and disease-free survival for CRC patients. He is currently studying the benefit of chemotherapy to help prevent recurrence, for patients who have had surgery for pancreatic cancer.
George Zogopoulos, MD
Dr. Zogopoulos is an assistant professor of surgery at McGill University, a hepato-pancreato-biliary and abdominal organ transplant surgeon at the McGill University Health Centre, and a clinician-scientist at the Rosalind and Morris Goodman Cancer Research Centre and the Research Institute of the McGill University Health Centre. He is also a member of PCCF’s PancOne™ research project.
He is a scholar of the Fonds de Recherche du Québec – Santé, with a translational research program in pancreatic cancer. Dr. Zogopoulos established and directs the Quebec Pancreas Cancer Study, a familial pancreatic cancer and peri-ampullary tumour research registry.
His research focuses on the genetics and molecular subtypes of pancreatic cancer and includes a clinical screening program for individuals at increased risk for pancreatic cancer.